Andrew S. Ittleman/LinkedIn
Nov 5, 2025, 05:27
Andrew S. Ittleman: Florida’s New Stem Cell Laws Raise FDA and Patient Safety Concerns
Andrew S. Ittleman, Owner at Fuerst Ittleman David & Joseph, shared on LinkedIn:
”In July, Florida passed new “stem cell therapy” laws, which allow physicians to administer allogeneic “stem cell” products to patients. Among other problems with Florida’s new stem cell laws, they (i) authorize products which FDA prohibits, (ii) do not define “stem cell,” (iii) create a risk of patient confusion.
We have decades of history to understand the potential consequences of these laws, but that history seems to have been ignored during the legislative process. I explore these issues in the article available at the link below.”
Find more information here.
Stay informed with Hemostasis Today.
-
Jul 11, 2026, 09:48International Collaboration in Antithrombotic Stewardship – Anticoagulation Forum
-
Jul 11, 2026, 09:45Presenting New CRP-A Data at ISTH 2026 – Pplus Medical Limited
-
Jul 11, 2026, 09:41David Smadja: Addressing the Hidden Threat of Medical Misinformation at ISTH 2026
-
Jul 11, 2026, 09:40Dianne E. van der Wal: The Latest Advances in Hemostasis and Thrombosis on First Day of ISTH 2026
-
Jul 11, 2026, 09:34Heading to ISTH 2026 in Paris Join our session on patient led VTE education – NBCA
-
Jul 11, 2026, 09:33Flora Peyvandi: Empowering the Next Generation of ISTH
-
Jul 11, 2026, 09:28Ruah Alyamany: Surgical and Procedural Bleeding Risk – Perioperative AC guidance
-
Jul 11, 2026, 09:24Habib Bennaceur: New Perspectives on Patient-Centered Hemophilia Care at ISTH 2026
-
Jul 11, 2026, 09:01Nathan Connell: Celebrating 100 Years of von Willebrand Disease at ISTH 2026